FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095296444> ?p ?o ?g. }

• W3095296444 endingPage "225" @default.
• W3095296444 startingPage "218" @default.
• W3095296444 abstract "Recently, it has been suggested that glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), which play important roles in the homeostasis of glucose metabolism, could be involved in the regulation of bone metabolism. Inhibitors of dipeptidyl peptidase 4 (DPP-4), an enzyme that degrades GIP and GLP-1, are widely used clinically as a therapeutic agent for diabetes. However, the effects of DPP-4 inhibitors on bone metabolism remain unclear. In this study, we investigated the effects of linagliptin, a DPP-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus (T2DM). Non-diabetic mice were used as controls, and T2DM mice were administered linagliptin orally on a daily basis for 12 weeks. In T2DM mice, decreased bone mineral density was observed in the lower limb bones along with low serum osteocalcin levels and high serum tartrate-resistant acid phosphatase-5b (TRAP) levels. In contrast, the decreased serum osteocalcin levels and increased serum TRAP levels observed in T2DM mice were significantly suppressed after the administration of linagliptin 30 mg/kg. Bone histomorphometric analysis revealed a reduced osteoid volume and osteoblast surface with an increase in the eroded surface and number of osteoclasts in T2DM mice. This decreased bone formation and increased bone resorption observed in the T2DM mice were suppressed and trabecular bone volume increased following the administration of 30 mg/kg linagliptin. Collectively, these findings suggest that linagliptin may improve the microstructure of trabecular bone by inhibiting both a decrease in bone formation and an increase in bone resorption induced by T2DM." @default.
• W3095296444 created "2020-11-09" @default.
• W3095296444 creator A5018544723 @default.
• W3095296444 creator A5028585034 @default.
• W3095296444 creator A5048211129 @default.
• W3095296444 creator A5054276880 @default.
• W3095296444 creator A5068688596 @default.
• W3095296444 creator A5076256984 @default.
• W3095296444 creator A5090422481 @default.
• W3095296444 date "2020-10-31" @default.
• W3095296444 modified "2023-10-18" @default.
• W3095296444 title "Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice" @default.
• W3095296444 cites W1572916580 @default.
• W3095296444 cites W1948111189 @default.
• W3095296444 cites W1997416444 @default.
• W3095296444 cites W2002961599 @default.
• W3095296444 cites W2004021898 @default.
• W3095296444 cites W2006573193 @default.
• W3095296444 cites W2006950202 @default.
• W3095296444 cites W2013082477 @default.
• W3095296444 cites W2015017251 @default.
• W3095296444 cites W2043397734 @default.
• W3095296444 cites W2054564814 @default.
• W3095296444 cites W2054677013 @default.
• W3095296444 cites W2066219800 @default.
• W3095296444 cites W2081276121 @default.
• W3095296444 cites W2081666098 @default.
• W3095296444 cites W2091272943 @default.
• W3095296444 cites W2096425957 @default.
• W3095296444 cites W2102392334 @default.
• W3095296444 cites W2103318165 @default.
• W3095296444 cites W2106440171 @default.
• W3095296444 cites W2120403731 @default.
• W3095296444 cites W2125637498 @default.
• W3095296444 cites W2132828650 @default.
• W3095296444 cites W2151616821 @default.
• W3095296444 cites W2153152770 @default.
• W3095296444 cites W2167397201 @default.
• W3095296444 cites W2530224228 @default.
• W3095296444 cites W2550915286 @default.
• W3095296444 cites W2560623673 @default.
• W3095296444 cites W2740131959 @default.
• W3095296444 cites W2747434128 @default.
• W3095296444 cites W2751487777 @default.
• W3095296444 cites W2904556508 @default.
• W3095296444 cites W2936456541 @default.
• W3095296444 cites W3004984638 @default.
• W3095296444 cites W4320800126 @default.
• W3095296444 doi "https://doi.org/10.5582/ddt.2020.03073" @default.
• W3095296444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33116039" @default.
• W3095296444 hasPublicationYear "2020" @default.
• W3095296444 type Work @default.
• W3095296444 sameAs 3095296444 @default.
• W3095296444 citedByCount "7" @default.
• W3095296444 countsByYear W30952964442021 @default.
• W3095296444 countsByYear W30952964442022 @default.
• W3095296444 countsByYear W30952964442023 @default.
• W3095296444 crossrefType "journal-article" @default.
• W3095296444 hasAuthorship W3095296444A5018544723 @default.
• W3095296444 hasAuthorship W3095296444A5028585034 @default.
• W3095296444 hasAuthorship W3095296444A5048211129 @default.
• W3095296444 hasAuthorship W3095296444A5054276880 @default.
• W3095296444 hasAuthorship W3095296444A5068688596 @default.
• W3095296444 hasAuthorship W3095296444A5076256984 @default.
• W3095296444 hasAuthorship W3095296444A5090422481 @default.
• W3095296444 hasBestOaLocation W30952964441 @default.
• W3095296444 hasConcept C126322002 @default.
• W3095296444 hasConcept C131075544 @default.
• W3095296444 hasConcept C134018914 @default.
• W3095296444 hasConcept C156490143 @default.
• W3095296444 hasConcept C160160445 @default.
• W3095296444 hasConcept C170033053 @default.
• W3095296444 hasConcept C181199279 @default.
• W3095296444 hasConcept C185592680 @default.
• W3095296444 hasConcept C2776541429 @default.
• W3095296444 hasConcept C2776886416 @default.
• W3095296444 hasConcept C2777180221 @default.
• W3095296444 hasConcept C2777391703 @default.
• W3095296444 hasConcept C2778881409 @default.
• W3095296444 hasConcept C2780031085 @default.
• W3095296444 hasConcept C2781469919 @default.
• W3095296444 hasConcept C2910068830 @default.
• W3095296444 hasConcept C3018667095 @default.
• W3095296444 hasConcept C55493867 @default.
• W3095296444 hasConcept C555293320 @default.
• W3095296444 hasConcept C673006 @default.
• W3095296444 hasConcept C71924100 @default.
• W3095296444 hasConcept C81880429 @default.
• W3095296444 hasConceptScore W3095296444C126322002 @default.
• W3095296444 hasConceptScore W3095296444C131075544 @default.
• W3095296444 hasConceptScore W3095296444C134018914 @default.
• W3095296444 hasConceptScore W3095296444C156490143 @default.
• W3095296444 hasConceptScore W3095296444C160160445 @default.
• W3095296444 hasConceptScore W3095296444C170033053 @default.
• W3095296444 hasConceptScore W3095296444C181199279 @default.
• W3095296444 hasConceptScore W3095296444C185592680 @default.
• W3095296444 hasConceptScore W3095296444C2776541429 @default.
• W3095296444 hasConceptScore W3095296444C2776886416 @default.

• next